[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardioversion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardioversion":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100558864","max---shock-clinical-trial-100558864",false,"NCT06556667","MAX - SHOCK Clinical Trial","Comparison of Maximum Energy Shocks From Two Defibrillator Vendors MAX - SHOCK- A Randomized Controlled Clinical Trial","MAX-SHOCK","Inclusion Criteria:\n\n* Patients age \\> 18 years.\n* Persistent atrial fibrillation.\n* Scheduled for elective cardioversion at UOHI\n* Patient is within the circle of care of UOHI Electrophysiology staff\n\nExclusion Criteria:\n\n* Known left-atrial appendage thrombus.\n* Contraindication to appropriate anticoagulation.\n* Patient is included in another randomized clinical trial.\n* Patient does not meet all of the above listed inclusion criteria.","ALL","18 Years",{"count":20,"type":21},376,"ESTIMATED","INTERVENTIONAL",[24],"NA","Can Electrical Cardioversion (ECV) for AF be improved. It is the preferred method to restore sinus rhythm in patients with AF in whom a rhythm-control strategy is pursued.\n\nHypothesis:\n\nECV success rates will be greater with a biphasic defibrillator with maximum energy of 360J (® Physio-Control) compared to a biphasic defibrillator with maximum energy of 200J (® Zoll)",[27,28],"Cardioversion","Atrial Fibrillation",[30],"defibrillator","RECRUITING","2026-01-30",{"date":34,"type":35},"2026-02-03","ACTUAL",{"date":37,"type":35},"2025-03-31",{"date":39,"type":21},"2027-09-01",{"name":41,"class":42},"Ottawa Heart Institute Research Corporation","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100608755","cardiovascular-performance-and-exercise-response-in-patients-with-persistent-or-permanent-atrial-fibrillation-and-heart-failure-pre-and-post-cardioversion-or-pace-and-ablate-100608755","NCT07205679","Cardiovascular Performance and Exercise Response in Patients With Persistent or Permanent Atrial Fibrillation and Heart Failure Pre and Post Cardioversion or Pace and Ablate","CPEX-CPA","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Persistent or Permanent Atrial Fibrillation\n3. HF - NYHA class II-IVA despite guideline-direct medical therapy\n4. Rate controlled\n5. Able to perform stress test\n6. Scheduled for clinical P\\&A OR cardioversion\n\nExclusion Criteria:\n\n1. Creatinine \\>180 μmol\u002FL or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2\n2. Significant valvular heart disease: Moderate to severe tricuspid regurgitation, mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis\n3. Patients who have had a TAVI, valvular surgery, or CABG within 3 months of enrolment\n4. Right ventricular systolic pressure \\>50mmHg\n5. Existing pacemaker\n6. In sinus rhythm\n7. Predictable vasovagal syncope to pain and sight of blood",{"count":52,"type":21},40,"OBSERVATIONAL","Heart Failure (HF) and Atrial Fibrillation (AF) are two conditions that commonly occur together. Clinical guidelines consider a resting heart rate of 100-110 beats per minute (bpm) acceptable for patients with HF and AF while 72 bpm is considered the average in healthy populations. A higher resting heart rate indicates that the heart is working harder to meet bodily demands, and though it may be considered safe for patients with HF and AF to have a heart rate of 110 bpm, the investigators believe it is having a significant negative impact on patient quality of life and their ability to exercise. The current study will test exercise ability using a treadmill test before and after either a cardioversion, where the patient's heartbeat is reset using electric shocks, or a pace and ablate method, where the patient receives a pacemaker to regulate their heart rhythm and an ablation (intentional damaging) of the node that coordinates the beats within the heart. This will allow investigators to compare how the heart responds to exercise when the patient is on rate-control and anticoagulation medication therapy (before cardioversion or pace and ablate) and after the procedures. During exercise, the investigators will do a blood test that lets investigators know how efficiently the heart is working and record any symptoms experienced. The investigators will also collect information about the patient's quality of life. Using this information, the investigators hope to better understand whether the current standard of a resting heart rate of 100-110 bpm is ideal for patient quality of life.",[56,57,58,27,59],"Atrial Fibrillation (AF)","Heart Failure - NYHA II - IV","Pacemaker","Ablation Therapy",[61],"Cardiopulmonary Exercise Testing","NOT_YET_RECRUITING","2025-10-01",{"date":65,"type":35},"2025-10-03",{"date":63,"type":21},{"date":68,"type":21},"2026-07",{"name":70,"class":42},"Habib Khan"]